-
King of the world, Abexili combined with endocrine therapy for Chinese patients with early breast cancer, the risk of postoperative recurrence is greatly reduced by 34.3%
Time of Update: 2021-06-22
Based on this, monarchE research came into being as needed, through the combined use of CDK4/6 inhibitors and endocrine therapy drugs for the adjuvant treatment of hormone receptor-positive but HER2-negative breast cancer with a high risk of recurrence .
-
Advanced Materials breakthrough!
Time of Update: 2021-06-22
The paper, the study describes a liposomal drug delivery system (S1P/JS-K/Lipo) that delivers nitric oxide (NO) prodrug JS-K, using sphingosine 1-phosphate (S1P) signaling The molecule acts as an active targeting lipid ligand and acts on GBM tumors .
-
Starting from the tumor microenvironment, CRISPR/Cas9 gene editing CAR-T exerts powerful effects
Time of Update: 2021-06-22
Many studies have shown that CRISPR/Cas9-mediated deletion of various inhibitory genes (including PD-1, TGFβR and PTPN2) has been proven effective in many types of tumor models; and gene editing PD-1 T cells The therapy has now entered the stage of clinical trials .
-
Nat Commun: p32 CAR-T cells: a potential treatment option for glioblastoma
Time of Update: 2021-06-21
immunityAnalysis of the expression level of p32 in the sampleAnalysis of the expression level of p32 in the sampleIn this study, the researchers found that p32/gC1qR/HABP/C1qBP is specifically expressed on the surface of glioma cells, which has also become a suitable tumor-associated antigen for redirecting CAR-T cell therapy .
-
Chinese clinical diagnosis and treatment guidelines for malignant pleural mesothelioma (2021 version), 5 minutes get the main points!
Time of Update: 2021-06-21
Pleural mesothelioma is a derived from skin cells or other parts of rare tumor, which is derived from the pleural about 81 %, other portions bits comprises peritoneal, pericardial and the like tunica
-
Lancet oncol: Pralsetinib is expected to be used in the treatment of RET fusion-positive NSCLC
Time of Update: 2021-06-21
NSCLC This study aims to evaluate the safety, tolerability and anti-tumor activity of pratinib (Pralsetinib, a highly effective, oral and selective RET inhibitor) for RET fusion-positive NSCLC patientsThe ARROW trial is a multi-cohort, open-label Phase 1/2 study conducted in 71 locations in 13 countries, recruiting patients with locally advanced or metastatic solid tumors over 18 years of age, including NSCLC with RET fusion-positive NSCLC Patient .
-
Brit J Cancer: The effect of microwave ablation in the treatment of patients with non-small cell lung cancer after radical resection
Time of Update: 2021-06-21
Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer .
https:// yMulticentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer in this message
-
Brit J Cancer: Mammography Microcalcification and Breast Cancer Risk
Time of Update: 2021-06-21
diagnosisIt can be seen that microcalcification foci is an independent risk factor for BC, and the estimated risk of premenopausal women is higher .
Microcalcification foci are an independent risk factor for BC, and premenopausal women have a higher estimated risk .
-
Immune "Gemini" was approved by the National Medical Products Administration for the first-line treatment of malignant pleural mesothelioma
Time of Update: 2021-06-21
Management ImmunityThis approval is based on a clinical study called CheckMate-743, which is the first and currently the only proof that first-line dual immunotherapy compared to standard platinum-containing chemotherapy can bring survival benefits to all patients with malignant pleural mesothelioma (MPM) A randomized, phase III clinical study .
-
European Urology: The role of popular target CD38 in advanced prostate cancer
Time of Update: 2021-06-21
The research results were published in the journal European Urology, let us find out!Recently, researchers have explored the expression characteristics of CD38 on prostate cancer (PC) epithelial cells and TIICs, and linked its expression to clinical results .
-
Lancet oncol: The efficacy of levatinib combined with pembrolizumab in the treatment of metastatic renal cell carcinoma can be expected!
Time of Update: 2021-06-21
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study .
1016/S1470-2045(21)00241-2Lenvatinib plus pembrolizumab in patients with either treatment -naive or previously treated metastatic renal cell carcinoma (Study 111 / KEYNOTE-146): a phase 1b / 2 study in this message
-
Lancet oncol: avelumab alone or combined with PLD can significantly prolong the survival prognosis of platinum-resistant/refractory ovarian cancer
Time of Update: 2021-06-21
Compared with PLD alone, avelumab combined with PLD or avelumab alone can significantly prolong the progression-free survival and overall survival of platinum-resistant or refractory ovarian cancer, fallopian tube cancer, and peritoneal cancer.
-
Genet Med: The clinical applicability of PALB2 and CHEK2 c.1100delC detection in breast-ovarian cancer
Time of Update: 2021-06-21
About 4% of breast cancer cases carry high-risk pathogenic germline gene variantsThis study aims to evaluate the contribution of PALB2 pathogenic variants (PALB2-PGV) and CHEK2 c.
PALB2-PGV showed perfect separation among the 20/20 first-degree relatives of breast cancer patients, but the ratio of CHEK2-1100delC was only 7/13 (p=0.
-
WHO warns that e-waste has affected the health of millions of children
Time of Update: 2021-06-21
”"The health sector can play a role by providing leadership and advocacy, conducting research, influencing decision makers, involving the community, and engaging with other sectors, requiring health issues to be the core of e-waste policy .
-
J Immunother Cancer: Efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma
Time of Update: 2021-06-21
Common adverse events Common adverse eventsIn summary, studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future .
-
Metz Tumor Progress Express (Issue 009)
Time of Update: 2021-06-21
Cancers: The clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: a prospective COLOSPOT studyThe research team from France constructed the CK19-EPISPOT assay and carried out a prospective study COLOSPOT, mainly using the CK19-EPISPOT assay and CellSearch ®system to detect CTCs, and to evaluate the use of FOLFIRI-bevacizumab in the treatment of CTCs.
-
JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma
Time of Update: 2021-06-21
FOXR2 Stabilizes MYCN Protein and Identifies Non-Amplified Neuroblastoma Patients With Unfavorable Outcome .
02540FOXR2 Stabilizes MYCN Protein and Identifies Non- Amplified Neuroblastoma Patients With Unfavorable Outcome in this message
-
Cancers: Efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors: from a Meta analysis
Time of Update: 2021-06-21
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC .
-
ESMO Open: Tumor mutation burden can predict the prognosis of patients with oral squamous cell carcinoma
Time of Update: 2021-06-21
To explore the molecular profile of oral squamous cell carcinoma (OCSCC), and to evaluate the tumor mutational burden (TMB) and the prognostic significance of classical molecular and clinical parametersEnrolled 151 OCSCC patients who underwent preoperative treatment at Institut Curie .
-
Brit J Cancer: The significance of the ratio of neutrophils to lymphocytes to the prognosis and diagnosis of patients with hepatocellular carcinoma
Time of Update: 2021-06-21
The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study .
https:// 021-01445-3The prognostic and diagnostic significance of the neutrophil -to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study in this message
